Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
1.
Phys Rev E ; 106(4-1): 044205, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36397537

ABSTRACT

In the present work, we focus on two dynamical timescales in the Arnold Hamiltonian model: the Lyapunov time and the diffusion time when the system is confined to the stochastic layer of its dominant resonance (guiding resonance). Following Chirikov's formulation, the model is revisited, and a discussion about the main assumptions behind the analytical estimates for the diffusion rate is given. On the other hand, and in line with Chirikov's ideas, theoretical estimations of the Lyapunov time are derived. Later on, three series of numerical experiments are presented for various sets of values of the model parameters, where both timescales are computed. Comparisons between the analytical estimates and the numerical determinations are provided whenever the parameters are not too large, and those cases are in fact in agreement. In particular, the case in which both parameters are equal is numerically investigated. Relationships between the diffusion time and the Lyapunov time are established, like an exponential law or a power law in the case of large values of the parameters.

2.
Pathogens ; 10(5)2021 Apr 26.
Article in English | MEDLINE | ID: mdl-33925986

ABSTRACT

In this study, we report on the full genome phylogenetic analysis of four ASFV isolates obtained from wild boars in Russia. These samples originated from two eastern and two western regions of Russia in 2019. Phylogenetic analysis indicated that the isolates were assigned to genotype II and grouped according to their geographical origins. The two eastern isolates shared 99.99% sequence identity with isolates from China, Poland, Belgium, and Moldova, whereas the western isolates had 99.98% sequence identity with isolates from Lithuania and the original Georgia 2007 isolate. Based on the full genome phylogenies, we identified three single locus targets, MGF-360-10L, MGF-505-9R, and I267L, that yielded the same resolving power as the full genomes. The ease of alignment and a high level of variation make these targets a suitable selection as additional molecular markers in future ASFV phylogenetic practices.

3.
Oncoimmunology ; 9(1): 1744946, 2020 04 09.
Article in English | MEDLINE | ID: mdl-33457090

ABSTRACT

Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expressing T cells in tumors and spleens. Importantly, these ectonucleotidase-positive T cells also showed a pronounced expression of PD-1. Conversely, the PD-1+ T cell subsets in tumors contained substantially larger proportions of ectonucleotidase-expressing cells compared to their counterparts lacking PD-1 expression. Our in vitro experiments showed that the activation of normal T cells resulted in an increase in the CD39 expression. CD39+ and CD73+ T cells displayed effector or memory phenotypes and produced IFN-γ, thereby linking ectonucleotidase expression to T cell effector functions. An accumulation of conventional and regulatory T cells expressing CD39 and/or CD73 was also detected in the peripheral blood of patients with melanoma and pancreatic cancer. Moreover, we demonstrated a significant association between low frequencies of circulating CD73+CD8+ T cells and CD73+CD4+ regulatory T cells and better overall survival of melanoma patients. Tumor-derived soluble factors (in particular, TGF-ß) significantly enhanced the frequencies of ectonucleotidase-expressing cells in mice. Our findings suggest that the upregulation of ectonucleotidase expression in T cells promotes extracellular adenosine accumulation and represents an important mechanism of homeostatic immune auto-regulation, which could be hijacked by tumors to evade anti-cancer immunity. Targeting CD39 and CD73 can open new avenues for cancer immunotherapy.


Subject(s)
Adenocarcinoma , Pancreatic Neoplasms , Animals , CD8-Positive T-Lymphocytes , Humans , Immunity , Mice , Pancreatic Neoplasms/genetics , T-Lymphocyte Subsets , Tumor Microenvironment
4.
Vet Sci ; 6(4)2019 Dec 06.
Article in English | MEDLINE | ID: mdl-31817809

ABSTRACT

Biological properties of the African swine fever (ASF) virus isolates originating from various regions of the Russian Federation (2013-2018) were studied in a series of experimental infections. Comparative analysis allowed us to establish the differences in the key characteristics of the infection, such us the duration of the incubation periods, disease, and the onset of death. The incubation period averaged 4.1 days, varying from 1 to 13 days. An average duration of the disease was 6.3 days and varied from 0 to 18 days. Overall case fatality was 94.5%, and antibodies were detected only in 19.3% of the animals. The biological properties of isolates Odintsovo 02/14 and Lipetsk 12/16 were significantly different from others. For this two, the presence of antibodies to the virus was detected in 71.4% and 75% of animals respectively and mortality levels were of 87.5% and 50%.

5.
Front Immunol ; 9: 1816, 2018.
Article in English | MEDLINE | ID: mdl-30131808

ABSTRACT

Novel therapies targeting immune checkpoint molecules have redefined the treatment of cancer at advanced stages and brought hope to millions of patients worldwide. Monoclonal antibodies targeting immune-inhibitory receptors often lead to complete and objective responses as well as to durable progression-free survival where all other therapeutic approaches fail. Yet, many tumors show significant resistance to checkpoint blockade through mechanisms that are only starting to come to light. An alluring alternative strategy to reinvigorate anticancer immune responses comes from the emerging field of immuno-metabolism. Over the past few years, numerous studies revealed that many well-known metabolic playmakers also serve as critical checkpoints in immune homeostasis and immunity against tumors. Here, we survey recent insights into the intimate and intertwining links between T cell metabolic programs and environmental cues in the tumor milieu. Transferring these new findings from the bench to the bedside may soon entirely re-shape the field of cancer immunotherapy and significantly improve the lives of patients.


Subject(s)
Antineoplastic Agents, Immunological/therapeutic use , Biomarkers, Tumor , Energy Metabolism/drug effects , Neoplasms/immunology , Neoplasms/metabolism , Neoplasms/therapy , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Animals , Antineoplastic Agents, Immunological/pharmacology , Cell Differentiation/immunology , Humans , Immunomodulation/drug effects , Immunotherapy , Metabolic Networks and Pathways/drug effects , Oxygen/metabolism , Signal Transduction/drug effects , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Tumor Microenvironment/drug effects , Tumor Microenvironment/immunology
6.
JCI Insight ; 3(2)2018 01 25.
Article in English | MEDLINE | ID: mdl-29367462

ABSTRACT

T cell receptor (TCR) affinity is a critical factor of Treg lineage commitment, but whether self-reactivity is a determining factor in peripheral Treg function remains unknown. Here, we report that a high degree of self-reactivity is crucial for tissue-specific Treg function in autoimmunity. Based on high expression of CD5, we identified a subset of self-reactive Tregs expressing elevated levels of T-bet, GITR, CTLA-4, and ICOS, which imparted significant protection from autoimmune diabetes. We observed that T-bet expression in Tregs, necessary for control of Th1 autoimmunity, could be induced in an IFNγ-independent fashion and, unlike in conventional T cells (Tconv), was strongly correlated with the strength of TCR signaling. The level of CD5 similarly identified human Tregs with an increased functional profile, suggesting that CD5hi Tregs may constitute an efficacious subpopulation appropriate for use in adoptive Treg therapies for treatment of inflammatory conditions. Overall, this work establishes an instrumental role of high TCR self-reactivity in driving Treg function.


Subject(s)
Autoimmunity , Diabetes Mellitus, Type 1/immunology , Receptors, Antigen, T-Cell/metabolism , T-Box Domain Proteins/metabolism , T-Lymphocytes, Regulatory/immunology , Adult , Animals , CD5 Antigens , Cells, Cultured , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/therapy , Disease Models, Animal , Female , Healthy Volunteers , Humans , Immunotherapy, Adoptive/methods , Islets of Langerhans , Male , Mice , Mice, Inbred NOD , Mice, SCID , Mice, Transgenic , Primary Cell Culture , Receptors, Antigen, T-Cell/genetics , Receptors, Antigen, T-Cell/immunology , T-Box Domain Proteins/immunology , T-Lymphocytes, Regulatory/metabolism , T-Lymphocytes, Regulatory/transplantation , Young Adult
7.
J Immunol ; 200(3): 909-914, 2018 02 01.
Article in English | MEDLINE | ID: mdl-29282307

ABSTRACT

Regulatory T cells (Tregs) use a distinct TCR repertoire and are more self-reactive compared with conventional T cells. However, the extent to which TCR affinity regulates the function of self-reactive Tregs is largely unknown. In this study, we used a two-TCR model to assess the role of TCR affinity in Treg function during autoimmunity. We observed that high- and low-affinity Tregs were recruited to the pancreas and contributed to protection from autoimmune diabetes. Interestingly, high-affinity cells preferentially upregulated the TCR-dependent Treg functional mediators IL-10, TIGIT, GITR, and CTLA4, whereas low-affinity cells displayed increased transcripts for Areg and Ebi3, suggesting distinct functional profiles. The results of this study suggest mechanistically distinct and potentially nonredundant roles for high- and low-affinity Tregs in controlling autoimmunity.


Subject(s)
Autoimmunity/immunology , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/prevention & control , Receptors, Antigen, T-Cell/immunology , T-Lymphocytes, Regulatory/immunology , Amphiregulin/biosynthesis , Animals , CTLA-4 Antigen/biosynthesis , Cell Adhesion/immunology , Glucocorticoid-Induced TNFR-Related Protein/biosynthesis , Interleukin-10/biosynthesis , Mice , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Minor Histocompatibility Antigens/biosynthesis , Pancreas/cytology , Pancreas/immunology , Receptors, Cytokine/biosynthesis , Receptors, Immunologic/biosynthesis
8.
Arch Immunol Ther Exp (Warsz) ; 66(2): 89-96, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29026920

ABSTRACT

The progress in melanoma immunotherapy highlights the importance of immunotherapy for cancer treatment. Although the concept of immunotherapy emerged in the beginning of the twentieth century, the end of the century signaled the start of modern immunotherapy, which has recently allowed a staggering progress in the field of cancer immunotherapy. Currently, there is a wide variety of immunotherapeutic approaches and critical improvements are continually being made. Among different immunotherapeutic strategies, therapies based on the blockade of immune checkpoint molecules have shown unparalleled efficacy in late-stage cancer patients. Pre-clinical research using ex vivo and in vivo approaches demonstrates the promise of numerous novel strategies for the immunotherapy of cancer.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Cancer Vaccines/immunology , Immunotherapy/methods , Neoplasms/therapy , Animals , Combined Modality Therapy , Costimulatory and Inhibitory T-Cell Receptors/immunology , Cytokines/immunology , Drug Evaluation, Preclinical , Humans , Neoplasms/immunology
9.
Oncoimmunology ; 6(9): e1326440, 2017.
Article in English | MEDLINE | ID: mdl-28932631

ABSTRACT

Myeloid-derived suppressor cells (MDSCs) are known to play a critical role in the suppression of T cell antitumor responses. Our preclinical data showed that the phosphodiesterase (PDE)-5 inhibitor sildenafil impaired MDSC functions, enhanced intratumoral T cell activity and prolonged survival of melanoma-bearing mice. In this study, we evaluated biologic effects, safety and efficacy of palliative treatment with the PDE-5 inhibitor tadalafil in metastatic melanoma patients. We conducted an open-label, dose de-escalation trial with tadalafil in pretreated metastatic melanoma patients. Tumor and peripheral blood samples were taken before and 4 weeks after the start of treatment. Samples were investigated by immunohistochemistry and FACS analysis, for different immune subsets with numbers of CD8+ tumor-infiltrating lymphocytes (TIL) as primary end point. Stable disease was achieved in 3/12 patients (25%). Median progression-free survival was 4.6 mo (range 0.7-7.1), median overall survival (OS) 8.5 mo (range 2.7-23.7). The treatment was well tolerated. Stable patients displayed significantly higher numbers of CD8+ TIL in the center of metastases before treatment as compared with progressive patients. Upon the therapy, they showed increased expression of ζ-chain (used as a marker of T cell activation) in CD8+ and CD4+TILs and CD8+T cells in the peripheral blood as compared with baseline. Our study suggests that the PDE-5 inhibitor tadalafil can improve clinical outcome of advanced melanoma patients by enhancing antitumor immunity and highlights its potential application in combined melanoma immunotherapy.

10.
J Vis Exp ; (113)2016 07 11.
Article in English | MEDLINE | ID: mdl-27500835

ABSTRACT

T cell receptor (TCR) signaling is essential in the development and differentiation of T cells in the thymus and periphery, respectively. The vast array of TCRs proves studying a specific antigenic response difficult. Therefore, TCR transgenic mice were made to study positive and negative selection in the thymus as well as peripheral T cell activation, proliferation and tolerance. However, relatively few TCR transgenic mice have been generated specific to any given antigen. Thus, studies involving TCRs of varying affinities for the same antigenic peptide have been lacking. The generation of a new TCR transgenic line can take six or more months. Additionally, any specific backcrosses can take an additional six months. In order to allow faster generation and screening of multiple TCRs, a protocol for retroviral transduction of bone marrow was established with stoichiometric expression of the TCRα and TCRß chains and the generation of retrogenic mice. Each retrogenic mouse is essentially a founder, virtually negating a founder effect, while the length of time to generate a TCR retrogenic is cut from six months to approximately six weeks. Here we present a rapid and flexible alternative to TCR transgenic mice that can be expressed on any chosen background with any particular TCR.


Subject(s)
Mice, Transgenic , Receptors, Antigen, T-Cell/genetics , Retroviridae , Stem Cells/cytology , Transduction, Genetic/methods , Animals , Bone Marrow , Mice , T-Lymphocytes , Thymus Gland
11.
Oncoimmunology ; 4(4): e998519, 2015 Apr.
Article in English | MEDLINE | ID: mdl-26137414

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) represents one of the deadliest cancers in the world. PDAC cells activate tumor-specific immune responses but simultaneously trigger a strong immunosuppression. We showed that PDAC cells produce high amount of chronic inflammatory mediators and PDAC tumors build an immunosuppressive cytokine milieu, which correlates with tumor progression. We observed a low frequency of dendritic cells (DC) and a pronounced accumulation of macrophages and myeloid-derived suppressor cells (MDSC) in murine PDAC tumors. A strong accumulation of MDSC has also been demonstrated in the peripheral blood of resected PDAC patients. While DC and macrophages seem not to play a significant role in this PDAC model in the context of immunosuppression, MDSC are highly suppressive, and their accumulation is associated with an increase in intratumoral VEGF concentration during the PDAC progression. Application of the phosphodiesterase-5 inhibitor sildenafil led to a prolonged survival of PDAC-bearing female mice, which was due to the decrease in MDSC frequencies and in the systemic VEGF level. This led to a restoration of anticancer immune responses, manifested in the recovery of T lymphocyte functions and in an increase in the frequency of conventional CD4+ T cells in tumors and IFNγ level in serum of PDAC-bearing mice. Thus, MDSC are strongly involved in the PDAC-associated immunosuppression and that their depletion could create new approaches for therapy of PDAC.

12.
Mol Ther ; 22(11): 1949-59, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25156126

ABSTRACT

We hypothesized that the combination of oncolytic virotherapy with immune checkpoint modulators would reduce tumor burden by direct cell lysis and stimulate antitumor immunity. In this study, we have generated attenuated Measles virus (MV) vectors encoding antibodies against CTLA-4 and PD-L1 (MV-aCTLA-4 and MV-aPD-L1). We characterized the vectors in terms of growth kinetics, antibody expression, and cytotoxicity in vitro. Immunotherapeutic effects were assessed in a newly established, fully immunocompetent murine model of malignant melanoma, B16-CD20. Analyses of tumor-infiltrating lymphocytes and restimulation experiments indicated a favorable immune profile after MV-mediated checkpoint modulation. Therapeutic benefits in terms of delayed tumor progression and prolonged median overall survival were observed for animals treated with vectors encoding anti-CTLA-4 and anti-PD-L1, respectively. Combining systemic administration of antibodies with MV treatment also improved therapeutic outcome. In vivo oncolytic efficacy against human tumors was studied in melanoma xenografts. MV-aCTLA-4 and MV-aPD-L1 were equally efficient as parental MV in this model, with high rates of complete tumor remission (> 80%). Furthermore, we could demonstrate lysis of tumor cells and transgene expression in primary tissue from melanoma patients. The current results suggest rapid translation of combining immune checkpoint modulation with oncolytic viruses into clinical application.


Subject(s)
B7-H1 Antigen/metabolism , CTLA-4 Antigen/metabolism , Lymphocytes, Tumor-Infiltrating/metabolism , Melanoma, Experimental/therapy , Oncolytic Viruses/immunology , Animals , Genetic Vectors/administration & dosage , Measles virus/genetics , Measles virus/immunology , Measles virus/metabolism , Melanoma, Experimental/immunology , Mice , Oncolytic Virotherapy , Oncolytic Viruses/genetics , Oncolytic Viruses/metabolism , Treatment Outcome
13.
Cancer Immunol Immunother ; 63(10): 1073-80, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24756420

ABSTRACT

Malignant melanoma is characterized by the development of chronic inflammation in the tumor microenvironment, which leads to a strong immunosuppression associated with a rapid tumor progression. Adenosine is considered as one of the main immunosuppressive factors in the tumor environment. It is produced via enzymatic hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 localized on cell surface. Using the ret transgenic mouse melanoma model that closely mimics human melanoma, we demonstrated an increased frequency of ectonucleotidase-positive myeloid-derived suppressor cells (MDSCs) in melanoma lesions and lymphoid organs. Furthermore, we observed that conventional CD4(+)FoxP3(-) and CD8(+) T cells infiltrating melanoma lesions of ret transgenic mice were distinctly enriched in the CD39(+)CD73(+) subpopulation that co-expressed also PD-1. Ectonucleotidase expression was also up-regulated in CD4(+) and CD8(+) T cells upon activation. In addition, these ectoenzymes were largely found to be expressed on memory T cell compartment (in particular, on effector memory cells). Our data suggest that extracellular adenosine produced by regulatory T cells (Tregs) and MDSCs can suppress T cell effector functions through paracrine signaling. Another mechanism involves its production also by effector T cells and an inhibition of their anti-tumor reactivity via autocrine signaling as a part of the negative feedback loop. This mode of adenosine signaling could be also used by Tregs and MDSCs to enhance their immunosuppressive activity.


Subject(s)
Adenosine/metabolism , Melanoma/immunology , Melanoma/metabolism , Skin Neoplasms/immunology , Skin Neoplasms/metabolism , T-Lymphocytes/metabolism , Adenosine/immunology , Animals , Cell Line, Tumor , Humans , Mice , T-Lymphocytes/immunology
14.
Cancer Immunol Immunother ; 63(1): 59-65, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24129765

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human neoplasms, having extremely poor prognosis with a 5-year survival rate of <1 % and a median survival of 6 months. In contrast to other malignancies, pancreatic cancer is highly resistant to chemotherapy and targeted therapy. Therefore, new treatment options are urgently needed to improve the survival of patients with PDAC. Based on our data showing that patients with higher CD8+ T cell tumour infiltration exhibited prolonged overall and disease-free survival compared to patients with lower or without CD8+ T cell tumour infiltration, we suggested that immunotherapy could be a promising treatment option for PDAC. However, clinical data from the chemoradioimmunotherapy with interferon-α (IFN) trial did not point to an improved efficiency of chemoradiation combined with IFN as compared to chemoradiotherapy alone, suggesting an important role of the immune suppression induced by PDAC and/or unspecific immune stimulation. In support of this hypothesis, we found that the PDAC patients and experimental mice had an increased number of regulatory T cells and myeloid-derived suppressor cells. These results allowed us to conclude that PDAC provokes not only an anti-tumour immune response, but also strong immune suppression. Thus, we supposed that new immunotherapeutical strategies should involve not only stimulation of the immune system of PDAC patients, but also exert control over the tumour immune suppressive milieu.


Subject(s)
Carcinoma, Pancreatic Ductal/immunology , Carcinoma, Pancreatic Ductal/therapy , Immunotherapy/methods , Pancreatic Neoplasms/immunology , Pancreatic Neoplasms/therapy , Animals , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , Chemoradiotherapy/methods , Clinical Trials as Topic , Humans , Interferon-alpha/metabolism , Mice , Myeloid Cells/cytology , Neoplasms/immunology , Prognosis , Treatment Outcome
15.
Int J Cancer ; 133(1): 98-107, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23233419

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human neoplasms with extremely poor prognosis and a low survival rate. Immunosuppressive cell populations, e.g. regulatory T cells (Treg), appear to be important in PDAC, contributing to patient's poor prognosis. Therefore, we investigated the PDAC microenvironment with a focus on conventional and regulatory T cells in view of their potential therapeutic importance. We found that tumors from the murine Panc02 orthotopic model of PDAC were infiltrated with high numbers of Treg. Remarkably, these cells exhibited the effector/memory phenotype, suggesting their enhanced suppressive activity and higher proliferation capacity. Although we observed a steady increase in transforming growth factor-ß (TGF-ß) levels in the tumors, treatment with a specific inhibitor of TGF-ß receptor I kinase failed to abrogate Treg accumulation. A CCR4 antagonist did not affect Treg percentage in the tumor either. However, intense Treg cell division in the tumor microenvironment was demonstrated, suggesting local proliferation as a major mechanism of Treg accumulation in PDAC. Notably, this accumulation was reduced by low-dose gemcitabine administration, resulting in a modestly increased survival of PDAC mice. Our results provide an insight into mechanisms of immunosuppression in PDAC, suggesting an important role for proliferative expansion of effector/memory Treg. Low-dose gemcitabine therapy selectively depletes Treg, providing a basis for new modalities of PDAC therapy.


Subject(s)
Antimetabolites, Antineoplastic/pharmacology , Deoxycytidine/analogs & derivatives , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/immunology , T-Lymphocytes, Regulatory/drug effects , Administration, Metronomic , Animals , Antimetabolites, Antineoplastic/administration & dosage , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/immunology , Cell Proliferation , Deoxycytidine/administration & dosage , Deoxycytidine/pharmacology , Flow Cytometry , Lymphocyte Count , Mice , Neoplasms, Experimental , Pancreatic Neoplasms/pathology , Survival Analysis , Gemcitabine
16.
Phys Rev E Stat Nonlin Soft Matter Phys ; 85(6 Pt 2): 066202, 2012 Jun.
Article in English | MEDLINE | ID: mdl-23005191

ABSTRACT

Modern theoretical methods for estimating the width of the chaotic layer in the presence of prominent marginal resonances are considered in the perturbed pendulum model of nonlinear resonance. The fields of applicability of these methods are explicitly and precisely formulated. The comparative accuracy is investigated in massive and long-run numerical experiments. It is shown that the methods are naturally subdivided in classes applicable for adiabatic and nonadiabatic cases of perturbation. It is explicitly shown that the pendulum approximation of marginal resonance works well in the nonadiabatic case. In this case, the role of marginal resonances in determining the total layer width is demonstrated to diminish with increasing main parameter λ (equal to the ratio of the perturbation frequency to the frequency of small-amplitude phase oscillations on the resonance). Solely the "bending effect" is important in determining the total amplitude of the energy deviations of the near-separatrix motion at λ≳7. In the adiabatic case, it is demonstrated that the geometrical form of the separatrix cell can be described analytically quite easily by means of using a specific representation of the separatrix map. It is shown that the nonadiabatic (and, to some extent, intermediary) case is most actual, in comparison with the adiabatic one, for the physical or technical applications that concern the energy jumps in the near-separatrix chaotic motion.


Subject(s)
Models, Theoretical , Nonlinear Dynamics , Oscillometry/methods , Computer Simulation
18.
Phys Rev E Stat Nonlin Soft Matter Phys ; 81(6 Pt 2): 066216, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20866510

ABSTRACT

We consider statistics of the disruption and Lyapunov times in an hierarchical restricted three-body problem. We show that at the edge of disruption the orbital periods and the size of the orbit of the escaping body exhibit Lévy flights. Due to them, the time decay of the survival probability is heavy-tailed with the power-law index equal to -2/3, while the relation between the Lyapunov and disruption times is quasilinear. Applicability of these results in an "hierarchical resonant scattering" setting for a three-body interaction is discussed.

SELECTION OF CITATIONS
SEARCH DETAIL
...